These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases. Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992 [TBL] [Abstract][Full Text] [Related]
6. Current status and perspectives of immune checkpoint inhibitors for colorectal cancer. Hirano H; Takashima A; Hamaguchi T; Shida D; Kanemitsu Y; Jpn J Clin Oncol; 2021 Jan; 51(1):10-19. PubMed ID: 33205813 [TBL] [Abstract][Full Text] [Related]
7. The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer. Silva VS; Riechelmann RP; Mello CA; Felismino T; Taboada R Curr Cancer Drug Targets; 2022 Aug; 22(8):617-628. PubMed ID: 35209820 [TBL] [Abstract][Full Text] [Related]
8. Targeting MSS colorectal cancer with immunotherapy: are we turning the corner? Wang C; Fakih M Expert Opin Biol Ther; 2021 Oct; 21(10):1347-1357. PubMed ID: 34030532 [TBL] [Abstract][Full Text] [Related]
9. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001 [TBL] [Abstract][Full Text] [Related]
10. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer. Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035 [TBL] [Abstract][Full Text] [Related]
11. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer. Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. Ciardiello D; Vitiello PP; Cardone C; Martini G; Troiani T; Martinelli E; Ciardiello F Cancer Treat Rev; 2019 Jun; 76():22-32. PubMed ID: 31079031 [TBL] [Abstract][Full Text] [Related]
13. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors. Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945 [TBL] [Abstract][Full Text] [Related]
14. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells. Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085 [TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Microsatellite Stable Colorectal Cancers: Challenges and Novel Therapeutic Avenues. Sahin IH; Ciombor KK; Diaz LA; Yu J; Kim R Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-12. PubMed ID: 35658496 [TBL] [Abstract][Full Text] [Related]
16. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer. Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer. Mazzoli G; Cohen R; Lonardi S; Corti F; Elez E; Fakih M; Jayachandran P; Colle R; Shah AT; Salati M; Fenocchio E; Salvatore L; Ambrosini M; Ros J; Intini R; Cremolini C; Overman MJ; André T; Pietrantonio F Eur J Cancer; 2022 Sep; 172():171-181. PubMed ID: 35777274 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in Colorectal Cancer - Finding the Achilles' Heel. Park R; Saeed A NEJM Evid; 2024 Jun; 3(6):EVIDra2300353. PubMed ID: 38804784 [TBL] [Abstract][Full Text] [Related]
19. Chr20q Amplification Defines a Distinct Molecular Subtype of Microsatellite Stable Colorectal Cancer. Zhang B; Yao K; Zhou E; Zhang L; Cheng C Cancer Res; 2021 Apr; 81(8):1977-1987. PubMed ID: 33619118 [TBL] [Abstract][Full Text] [Related]
20. Prediction of response to immune checkpoint blockade in patients with metastatic colorectal cancer with microsatellite instability. Ratovomanana T; Nicolle R; Cohen R; Diehl A; Siret A; Letourneur Q; Buhard O; Perrier A; Guillerm E; Coulet F; Cervera P; Benusiglio P; Labrèche K; Colle R; Collura A; Despras E; Le Rouzic P; Renaud F; Cros J; Alentorn A; Touat M; Ayadi M; Bourgoin P; Prunier C; Tournigand C; Fouchardière C; Tougeron D; Jonchère V; Bennouna J; de Reynies A; Fléjou JF; Svrcek M; André T; Duval A Ann Oncol; 2023 Aug; 34(8):703-713. PubMed ID: 37269904 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]